Replies to post #103554 on Biotech Values

[genisi]

Teva attempted to have three additional Copaxone patents pertaining to molecular-weight markers [Nos. 6514938, 7074580, and 7163802] included in the litigation, but this request was denied by the Court.

I heard that on the 19-Jan-2011 Mylan/Natco Markman hearing these molecular-weight markers related patents (there's another one, see link) were discussed.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7615359.PN.&OS=PN/7615359&RS=PN/7615359